||WO||WO/2014/122639 - SHOCK PROTECTION FOR WEAPON MOUNTED DEVICES||14.08.2014||
||PCT/IL2013/050115||MEPROLIGHT LTD||VERBA, Gregory|
A device for mounting on a weapon or weapon station, including, an encasement (115) for enclosing the device, a core element (105) that provides a functionality of the device, a planar spring (140) that is connected internally to a side of the encasement; and wherein the core element is coupled to one side of the planar spring, so that the core element is not in physical contact with the encasement.
||WO||WO/2014/122645 - MULTIPLEXED SIGMA DELTA MODULATOR||14.08.2014||
||PCT/IL2014/050121||MICROSEMI CORP. - ANALOG MIXED SIGNAL GROUP, LTD.||DARSHAN, Yair|
A multiplexed sigma delta modulator constituted of: a control circuitry; a multiplexer responsive to the control circuitry and arranged to receive a plurality of input signals; a comparing circuit, a first input of the comparing circuit coupled to the output of the multiplexer; an integrator, the input of the integrator coupled to the output of the comparing circuit; a latched comparing circuit, one input of the latched comparing circuit coupled to the output of the integrator; a plurality of storage elements, each associated with one of the plurality of inputs; and a feedback circuit arranged to feedback the output of the latched comparing circuit to the second input of the comparing circuit, wherein the control circuitry is further arranged to store the charge of an element of the integrator on the associated storage element when the associated signal is not passed by the multiplexer to the output of the multiplexer.
||WO||WO/2014/122648 - POSITIVELY CHARGED POLYSACCHARIDES FOR RNA TRANSFECTION||14.08.2014||
||PCT/IL2014/050126||B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD.||KOST, Joseph|
A complex comprising RNA and a positively charged modified polysaccharide selected from starch, amylose, amylopectin, galactan, chitosan, or dextrin, pharmaceutical composition comprising it, and its use in RNA transfection are provided. Methods for RNA transfection, gene therapy and treatment of a disease, disorder or condition comprising using the complex are also provided. The use of positively charged modified polysaccharide selected from starch, amylose, amylopectin, galactan, chitosan, or dextrin, in RNA transfection into cells is further provided.
||WO||WO/2014/122650 - CABINET||14.08.2014||
||PCT/IL2014/050128||KETER PLASTIC LTD.||BRUNNER, Yaron|
The present disclosed subject matter is directed to a cabinet configured with at least a right side wall and a left side wall, defining together a cabinet space, closeable by a at least one front door pivotally articulated at a front portion of the cabinet and displaceable between a closed position and at least a first open position. At the first open position each of the at least one door is coplanar with a respective side wall and at least one of the right side wall and the left side wall are configured with wall rail segments. One or more of the respective at least one front door is configured with door rail segments, such that the wall rail segments are coextensive with respective door rail segments, with a sliding gap extending between neighboring ends of a wall rail segment and a door rail segment, and defining together one or more sliding planes. The planes are configured for slidingly supporting a support unit mountable thereon.
||WO||WO/2014/122644 - DEVICE AND METHODOLOGY FOR MEASURING MINUTE CHANGES IN AMBIENT MAGNETIC FIELD||14.08.2014||
||PCT/IL2014/050113||BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY||BEN AMAR BARANGA, Andrei|
An optical magnetometer comprising: a response frequency measurement unit comprising a vapor cell, a pulsed-mode pump laser and a probe laser; and a computing unit configured to compute a magnetic field change based on a difference between at least two temporally-distinct response frequency values received from the frequency measurement unit. Optionally, the response frequency measurement unit is magnetically non-shielded.
||WO||WO/2014/122646 - PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOF||14.08.2014||
||PCT/IL2014/050124||TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.||SHOENFELD, Yehuda|
The present invention provides phosphorylcholine (PC)-conjugates and pharmaceutical compositions, particularly vaccines comprising same for the prevention or treatment of autoimmune diseases. In particular, the PC-conjugates of the present invention are effective in preventing or treating autoimmune diseases associated with pathological inflammation.
||WO||WO/2014/122649 - FOLDABLE UMBRELLA||14.08.2014||
||PCT/IL2014/050127||ZULTI, Abraham||ZULTI, Abraham|
An umbrella is provided. The umbrella comprises a frame and a canopy attached thereto. The frame comprises a tube extending vertically along a tube axis, a cap at a top end of the tube, a runner configured to move along at least a portion of the tube, a plurality of ribs hingedly articulated to the cap, and a plurality of stretchers, each being hingedly articulated between the runner at a first point of attachment thereof, and one of the ribs at a second point of attachment thereof. Each of the caps comprises a disk projecting radially from the tube, the disk having a radial characteristic dimension which is more than one tenth the distance between the first and second points of attachment of the stretchers.
||WO||WO/2014/122651 - PROCESS FOR PREPARING INSULIN||14.08.2014||
||PCT/IL2014/050129||VALIN TECHNOLOGIES LTD.||HARTMAN, Jacob|
The present invention relates to an improved process for converting an insulin precursor into an active insulin compound, preferably a long-acting insulin. Specifically, this invention provides a process wherein lysine residues in a Lys-Arg precursor insulin are reversibly blocked thus enabling precise cleavage of the reversibly blocked Lys-Arg precursor insulin by trypsin.
||WO||WO/2014/122653 - PROCESS FOR PREPARING INSULIN||14.08.2014||
||PCT/IL2014/050131||VALIN TECHNOLOGIES LTD.||HARTMAN, Jacob|
The present invention relates to an improved process for converting an insulin precursor into an active insulin compound, preferably a long-acting insulin. Specifically, this invention provides a process wherein lysine residues in an Arg-Arg precursor insulin are reversibly blocked thus enabling cleavage of the reversibly blocked Arg-Arg precursor insulin by trypsin.
||WO||WO/2014/122654 - HYBRID NANOPORES AND USES THEREOF FOR DETECTION OF ANALYTES||14.08.2014||
||PCT/IL2014/050132||YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.||PORATH, Danny|
The invention relates to a hybrid structure comprising perforated solid substrate having at least one nanopore perforating therethrough, and devices and uses thereof.